Korea's Bambini Kids uses 8 motors, including a dedicated ankle joint, to guide children through natural overground walking instead of treadmill-based therapy.
Photo source:
cosmo
Most gait therapy for children with cerebral palsy happens on a
treadmill, with a harness holding them up while their legs move on command. It
works, to a point. But there's no real ground underfoot, no natural weight
shift, none of the small balance adjustments a child's brain needs to actually
learn the motion.
Cosmo Robotics, a South Korean company, built something different.
Bambini Kids is a wearable exoskeleton designed for preschool-age children with
cerebral palsy and other neurological gait disorders. It trains kids on real
ground, at their own pace, with joint-by-joint support that lets a small,
developing body relearn how walking actually feels.
Cerebral palsy stems from an early brain injury, and one of its most
common effects is a stiff or unstable gait. Catching it early — while a child's
body is still developing — matters more than treating it later.
Most rehab robots were built for adults, then scaled down. They typically
assist the hip and knee, since that's where the largest forces in walking
happen. But a complete gait cycle relies just as much on the ankle, which
controls how the foot rolls from heel strike to toe-off. Skip that motor, and
walking still looks artificial.
Korea's regulatory landscape reflects how narrow this space is. Of more
than 20 FDA-cleared exoskeletons, only one is built specifically for children.
In Korea, only two pediatric exoskeletons exist at all — and Bambini Kids is
the only one that actively assists the ankle alongside the hip and knee.
The device runs on eight motors. Four handle the familiar hip and knee
flexion most exoskeletons are built around. The other four handle what most
pediatric devices skip entirely: ankle dorsiflexion and plantarflexion, plus
hip abduction and adduction.
That dedicated ankle motor is the detail the whole device is built
around. As a child's foot moves through a step — heel down, weight rolling
forward, toes pushing off — the motor guides that motion directly, rather than
letting the foot drag passively. Cosmo Robotics says this produces a more
natural, symmetrical gait pattern.
The device adapts to severity, too. Children with more severe disorders
can train in passive mode, where the exoskeleton does most of the work.
Children with milder disorders use active mode, which assists rather than
leads, encouraging their own muscles to engage.
Safety runs on two levels. Therapists can hit an emergency stop at any
point. And the motors themselves detect sudden resistance — like spasticity —
and stop automatically before it becomes painful.
Bambini Kids is sized for children roughly 2.5 to 7 years old, around 100
cm tall — a narrow window on purpose. Fitting an exoskeleton to a body that
small, while still allowing natural joint movement, is harder than simply
scaling down an adult device.
Cosmo Robotics also makes Bambini Teens, a related device for older
children and adolescents, extending the same approach to school-age kids with
different bodies and walking patterns.
Cosmo Robotics is running a clinical study evaluating Bambini Kids'
safety and effectiveness in children with cerebral palsy, aiming to generate
evidence that supports approval in markets outside Korea. That caution fits the
field — robot-assisted gait training for young children is still a young area
of research, with most existing studies focused on older kids rather than
preschoolers.
A separate pilot study on adolescent exoskeleton training showed real
improvements in motor function and gait speed — encouraging, but evidence that
still needs building out for Bambini Kids' younger age group specifically.
The company showcased the device at CES 2026 and KIMES, Korea's largest
medical device exhibition. Cosmo Robotics — formerly ExoAtlet Asia — also
listed on Korea's KOSDAQ exchange in April 2026, with institutional demand
running over 1,000 times the available shares.
Please subscribe to have unlimited access to our innovations.